Rheumatology Practice Management August 2017 Vol 5 No 4
At the National Organization of Rheumatology Managers (NORM) 2017 Annual Conference, September 14-16, in Kansas City, MO, our expert speakers and educational sessions will help you further develop your management skills and successfully lead your practice into the future.
This article is focused on high-stakes claims appeals of the utmost difficulty, rather than the routine process. In rheumatology, such high stakes inherently will always entail a buy-and-bill specialty medication, such as a biologic or hyaluronan; to our newer colleagues, those medications are normally billed as J codes.
Although it is considered a “soft skill,” communication makes a tangible difference in quality of work, and in the quality of life of those doing the work. Effective communication can also be key in reducing costly misunderstandings and mistakes, and reducing office politics and power struggles.
In the office or clinic setting, a level 4 established patient office visit (CPT 99214) has always been the Evaluation and Management (E&M) code most physicians and nonphysician practitioners are cautious about billing to avoid payer scrutiny, yet they appreciate when they can bill it because the reimbursement is fair.
The following clinical trials represent a selection of key studies that are currently recruiting patients with rheumatoid arthritis for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist Approved for Moderately to Severely Active Rheumatoid Arthritis
Results 1 - 6 of 6